Global Endovascular Aneurysm Repair Devices Market Size By Type (Percutaneous EVAR, Fenestrated EVAR), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Endovascular Aneurysm Repair (EVAR) Devices Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 6.4 billion by 2031, growing at a CAGR of 9.5% during the forecast period (2023–2031). The growth is driven by the increasing prevalence of abdominal aortic aneurysms (AAAs), rising adoption of minimally invasive procedures, and advancements in EVAR technology. As an alternative to open surgical repair, EVAR devices offer reduced hospital stays, fewer complications, and quicker recovery, thereby fueling their global demand across both developed and emerging healthcare markets.

Drivers:

1. Rising Incidence of Abdominal Aortic Aneurysms (AAA):

An aging population, coupled with risk factors like hypertension, smoking, and atherosclerosis, has led to a growing number of AAA cases. EVAR provides a less invasive treatment option, significantly increasing its preference among patients and surgeons.

2. Preference for Minimally Invasive Surgery:

The global trend toward minimally invasive procedures is pushing EVAR adoption. These procedures reduce patient trauma, minimize surgical risks, and accelerate post-operative recovery, boosting market demand.

3. Technological Innovations in Stent Grafts:

Continual advancements in device design, including low-profile delivery systems, branched and fenestrated stent grafts, and image-guided navigation systems, are expanding the applicability and efficacy of EVAR solutions, enhancing their clinical success rates.

Restraints:

1. High Cost of EVAR Procedures and Devices:

Despite their benefits, EVAR procedures can be cost-prohibitive, particularly in lower-income countries, due to the expensive nature of stent grafts and the requirement for advanced imaging technologies.

2. Regulatory Hurdles and Reimbursement Challenges:

Strict regulatory approval pathways and limited reimbursement in certain regions may slow market expansion. Moreover, long-term follow-up requirements and device-related complications may affect physician preference.

Opportunity:

1. Expansion in Emerging Markets:

Asia-Pacific, Latin America, and the Middle East present untapped potential due to increasing healthcare expenditure, improved diagnostic facilities, and growing awareness of aneurysm-related complications.

2. Next-Generation Stent Grafts and Customization:

Companies are investing in personalized EVAR solutions tailored to patient-specific anatomy, such as 3D-printed and branched stent grafts. These innovations are expected to boost market penetration in complex and challenging aneurysm cases.

Market by System Type Insights:

By system type, the Standard EVAR Devices segment dominated in 2023 due to its widespread application in treating infrarenal abdominal aneurysms. However, the Fenestrated EVAR (FEVAR) Devices segment is anticipated to grow at the fastest pace owing to its increasing use in treating complex aneurysms involving branch vessels.

Market by End-use Insights:

In 2023, Hospitals accounted for the largest market share due to their access to advanced imaging, skilled vascular surgeons, and infrastructure for complex procedures. The Ambulatory Surgical Centers (ASCs) segment is expected to expand rapidly during the forecast period, driven by shorter procedure times and lower costs for outpatient treatments.

Market by Regional Insights:

North America led the market in 2023, supported by robust healthcare infrastructure, early adoption of advanced medical technologies, and high disease awareness. However, Asia-Pacific is expected to exhibit the highest CAGR due to rising healthcare investments, increasing prevalence of AAAs, and growing adoption of minimally invasive procedures.

Competitive Scenario:

Key players in the Global EVAR Devices Market include Medtronic plc, Cook Medical, W.L. Gore & Associates, Inc., Endologix LLC, Terumo Corporation, Lombard Medical, JOTEC GmbH (CryoLife Inc.), and Cardinal Health, Inc. These companies are focusing on strategic collaborations, product launches, and geographical expansion to strengthen their market positions.

Key Market Developments:

In 2023, Medtronic launched a next-generation endograft system with improved conformability and fixation features for challenging anatomies.

In 2024, Endologix announced FDA approval of its Alto™ endograft for AAA repair, emphasizing its low-profile delivery system.

In 2025, Cook Medical entered a strategic alliance with a European imaging firm to enhance intraoperative navigation for EVAR procedures.

Scope of Work – Global Endovascular Aneurysm Repair Devices Market

Report Metric Details

Market Size (2023) USD 3.1 Billion

Projected Market Size (2031) USD 6.4 Billion

CAGR (2023–2031) 9.5%

Market Segments By System Type (Standard EVAR, Fenestrated EVAR),

By End-use (Hospitals, ASCs)

Growth Drivers Increasing AAA cases, shift toward minimally invasive procedures, innovation in stent grafts

Opportunities Emerging markets expansion, patient-specific device customization

FAQs:

1) What is the current market size of the Global Endovascular Aneurysm Repair Devices Market?

The market was valued at USD 3.1 billion in 2023.

2) What is the major growth driver of the Global Endovascular Aneurysm Repair Devices Market?

The key driver is the increasing incidence of abdominal aortic aneurysms and preference for minimally invasive procedures.

3) Which is the largest region during the forecast period in the Global Endovascular Aneurysm Repair Devices Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Endovascular Aneurysm Repair Devices Market?

The Standard EVAR Devices segment dominated the market by system type in 2023.

5) Who are the key market players in the Global Endovascular Aneurysm Repair Devices Market?

Key players include Medtronic plc, Cook Medical, W.L. Gore & Associates, Endologix LLC, and Terumo Corporation.